Loperamide cases reported to United States poison centers, 2010-2022

Aaditya Patel; Natalie I Rine; Henry A Spiller; Hannah Hays; Jaahnavi Badeti; Motao Zhu; Kele Ding; Gary A Smith

doi:10.1186/s40621-023-00473-2

Loperamide cases reported to United States poison centers, 2010-2022

Inj Epidemiol. 2023 Nov 24;10(1):61. doi: 10.1186/s40621-023-00473-2.

Authors

Aaditya Patel^{1

2}, Natalie I Rine³, Henry A Spiller^{3

4}, Hannah Hays^{3

4}, Jaahnavi Badeti¹, Motao Zhu^{1

4}, Kele Ding¹, Gary A Smith^{5

6

7}

Affiliations

¹ Center for Injury Research and Policy, The Abigail Wexner Research Institute at Nationwide Children's Hospital, 700 Children's Drive, Columbus, OH, 43205, USA.
² Kansas City University College of Osteopathic Medicine, Kansas City, MO, USA.
³ Central Ohio Poison Center, Nationwide Children's Hospital, Columbus, OH, USA.
⁴ Department of Pediatrics, The Ohio State University College of Medicine, Columbus, OH, USA.
⁵ Center for Injury Research and Policy, The Abigail Wexner Research Institute at Nationwide Children's Hospital, 700 Children's Drive, Columbus, OH, 43205, USA. gary.smith@nationwidechildrens.org.
⁶ Department of Pediatrics, The Ohio State University College of Medicine, Columbus, OH, USA. gary.smith@nationwidechildrens.org.
⁷ Child Injury Prevention Alliance, Columbus, OH, USA. gary.smith@nationwidechildrens.org.

Abstract

Background: Intentional use of high doses of loperamide has been linked to serious cardiac toxicity. The objective of this study is to investigate the characteristics and trends of loperamide cases reported to United States (US) poison centers and to evaluate the changes in reported loperamide cases following US Food and Drug Administration (FDA) warnings, labeling requirements, and packaging restrictions for loperamide starting in 2016, with an emphasis on intentional exposures.

Methods: Data from the National Poison Data System were analyzed.

Results: There were 12,987 cases reported to US poison centers from 2010 to 2022, for which, loperamide was the most likely substance responsible for observed clinical effects. Although 46.1% of these cases were associated with minor or no effect, 13.4% resulted in a serious medical outcome, including 59 deaths (0.5%). Eight percent (8.1%) of cases were admitted to a critical care unit and 5.0% were admitted to a non-critical care unit. Among cases with a serious medical outcome, most were associated with loperamide abuse (38.0%), intentional-misuse (15.7%), or suspected suicide (27.5%). The majority (60.0%; n = 33) of fatalities were related to abuse, followed by suspected suicide (20.0%; n = 11) and intentional-misuse (5.5%, n = 3). The rate of loperamide cases per 100,000 US population reported to US PCs decreased from 0.44 in 2010 to 0.36 in 2015 (p = 0.0290), followed by an increase to 0.46 in 2017 (p = 0.0013), and then a trend reversal with a decrease to 0.28 in 2022 (p < 0.0001). The rate of serious medical outcomes related to loperamide increased from 0.03 in 2010 to 0.05 in 2015 (p = 0.0109), which subsequently increased rapidly to 0.11 in 2017 (p < 0.0001), and then demonstrated a trend reversal and decreased to 0.04 in 2022 (p < 0.0001).

Conclusions: FDA warnings, labeling requirements, and packaging restrictions may have contributed to the observed trend reversal and decrease in reports to US poison centers of loperamide cases related to intentional misuse, abuse, and suspected suicide. This demonstrates the potential positive effect that regulatory actions may have on public health. These findings contribute to the evidence supporting the application of similar prevention efforts to reduce poisoning from other medications associated with intentional misuse, abuse, and suicide.

Keywords: Abuse; Loperamide; Misuse; Poisoning; Suicide.